External validation of sTWEAK as a prognostic noninvasive biomarker for head and neck squamous cell carcinoma

Ximena Terra, David Gómez, Jacinto García-Lorenzo, Joan Carles Flores, Enric Figuerola, Josefina Mora, Matilde R. Chacón, Miquel Quer, Mercedes Camacho, Xavier León, Francesc Xavier Avilés-Jurado

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)

Abstract

© 2015 Wiley Periodicals, Inc.. Background The main purpose of this study was to validate the prognostic significance of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) in head and neck squamous cell carcinoma (HNSCC) using an independent cohort. Methods Data were evaluated from 153 patients with HNSCC in stages III to IV, who received radiotherapy (RT) or chemoradiotherapy. We quantified soluble TWEAK (sTWEAK) in pretreatment samples using enzyme-linked immunosorbent assay. Results The classification tree revealed a cutoff value of 322 pg/mL for sTWEAK to be ideal for discriminating between patients' disease control. Kaplan-Meier curves indicate that the disease-free survival rate in patients with high sTWEAK was significantly higher than in patients with low levels (p =.006, log-rank test). An independent link was identified between low sTWEAK and poor clinical outcome in Cox regression multivariate analysis (hazard ratio = 1.866; 95% confidence interval [CI] = 1.114-3.125; p =.001). Conclusion Our study highlights the significance of this noninvasive biomarker in the discrimination according to the disease control achieved by patients who received a nonsurgical organ-preservation treatment.
Original languageEnglish
Pages (from-to)E1358-E1363
JournalHead and Neck
Volume38
DOIs
Publication statusPublished - 1 Apr 2016

Keywords

  • disease-free survival
  • noninvasive biomarker
  • prognosis
  • soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK)
  • treatment

Fingerprint Dive into the research topics of 'External validation of sTWEAK as a prognostic noninvasive biomarker for head and neck squamous cell carcinoma'. Together they form a unique fingerprint.

Cite this